Skip to content


Translarna (ataluren) is a small molecule pharmaceutical. Ataluren was first approved as Translarna on 2014-07-31. It has been approved in Europe to treat duchenne muscular dystrophy.
Trade Name Translarna
Common Name Ataluren
Indication duchenne muscular dystrophy
Drug Class Inducers of ribossomal readthrough of nonsense mutation mRNA stop codons
Get full access now